HOME >> MEDICINE >> NEWS
CellCept associated with reduced incidence of cancer, compared to AZA, following heart transplant

San Francisco, April 23, 2004 - A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCept (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens. Presented at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT), the study found a 27% lower risk of cancer in CellCept-treated patients. Patients studied were part of the ISHLT Transplant Registry. "Though not derived from randomized controlled trials, these data indicate that the choice of maintenance immunosuppressive regimen may be a modifiable risk factor for the development of malignancy in heart transplant recipients," said James O'Neill, M.D., Fellow in Heart Failure and Cardiac Transplantation, Cleveland Clinic.

Previous research had shown that organ transplant recipients receiving immunosuppressive therapy are three to four times more likely to develop tumors than the general population and have an even greater risk of developing certain rare cancers.

Extensive Examination of Registry Validates CellCept Treatment
The study, Mycophenolate Mofetil and the Risk of Developing Malignancy Following Orthotopic Heart Transplantation (OHT), examined competing risk factors to determine which are associated with malignancy following OHT, and was based on 3,895 patients in the ISHLT Transplant Registry. The study examined survival without malignancy in patients taking standard immunosuppressive regimens (defined as cyclosporine or tacrolimus and azathioprine or CellCept), who underwent OHT between January 1, 1995, and December 31, 1997.

Of these patients, 703 (18%) developed malignancy during the follow-up period through June 30, 2002. The breakdown of malignancy was as follows: skin (47%), post-transplant lymphoproliferative disease (10%),
'"/>

Contact: Julip Cantre
Julio.Cantre@ketchum.com
917-204-0599
Ketchum
23-Apr-2004


Page: 1 2 3

Related medicine news :

1. New data supports CellCepts position as a world leader in solid organ transplantation
2. CellCept(R) registry data demonstrated superior long-term organ transplant outcomes
3. CellCepts cardioprotective profile reinforced
4. Data shows life of kidney transplant lengthened by CellCept
5. Organizational traits associated with quality patient care are essential to home care nursing
6. Depression may explain higher risk of heart attack associated with antidepressants
7. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
8. Inpatient smoking cessation counseling is associated with early differences in mortality
9. Hypothyroidism associated with reduced breast cancer risk
10. COX-2 inhibitors associated with blood pressure elevation
11. Mothers depression associated with increased risk of childs antisocial behavior

Post Your Comments:
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency Foundation (IDF) ... community using its IDF ePHR, an electronic personal health record powered by Get ... easily track their health information, including symptoms, diagnoses, medications, infusions and other critical ...
(Date:7/7/2015)... ... 07, 2015 , ... Parents and guardians of teenagers or young adults will ... holistic treatment center for drug and alcohol abuse located in Southwest Michigan. A recently ... shown a significant increase in the “club drug” use among high school seniors. The ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... of telemedicine programs in communities throughout Georgia, announces the launch of the first ... rural communities of Hancock County, GA. The new program will not only provide ...
(Date:7/7/2015)... NH (PRWEB) , ... July ... ... integrated, full-service public relations, marketing, and creative design firm, today announced that ... regional public relations and social media campaign, content strategy, and marketing launch ...
(Date:7/7/2015)... Horsham, PA (PRWEB) , ... July 07, 2015 ... ... seasoned financial executive Ellen Purdy as the company’s new Chief Financial Officer, effective ... financial and leadership experience in companies ranging from a multi-billion dollar, global chemical ...
Breaking Medicine News(10 mins):Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2Health News:Office Practicum Announces new CFO 2
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
(Date:7/7/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering of 32,000,000 units. Each unit consists of one share ... purchase one share of common stock at a purchase ... units in the offering would result in them beneficially ...
(Date:7/7/2015)... July 7, 2015 Oasmia ... of drugs within human and veterinary oncology, today ... in the United States , ... leading companion animal therapeutic.      (Logo: ... ) , Paccal Vet-CA1 was ...
Breaking Medicine Technology:Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
Cached News: